Mohammad Hossein Gozashti

Dr. Mohammad Hossein Gozashti


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Metabolism
Verified
Journal Article
Closed access
LNLaleh Razavi Nematollahi
Laleh Razavi Nematollahi
AKAbbas Eghbal Kitabchi
Abbas Eghbal Kitabchi
FSFrankie B. Stentz
Frankie B. Stentz
JWJim Y. Wan
Jim Y. Wan
BLBagher A. Larijani
Bagher A. Larijani
ETEghbal Taheri
Eghbal Taheri

27 October 2021 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
FYFarzaneh Yazdi
Farzaneh Yazdi
MBMohammad Hassan Baghaei
Mohammad Hassan Baghaei
ABAmir Baniasad
Amir Baniasad
ANAhmad Naghibzadeh‐Tahami
Ahmad Naghibzadeh‐Tahami
HNHamid Najafipour
Hamid Najafipour
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti
Aims: This study aimed to determine a parameter to more easily diagnose metabolic syndrome and predict its probability of occurrence in high‐risk individuals.Methods: In this cross‐sectional study, data related to the study population in the Kerman Coronary Artery Disease Risk Factor Study (KERCADRS) were examined. Subjects were divided into two groups with and without metabolic syndrome, and the relevant factors such as the ratios of uric acid to high‐density lipoprotein (HDL) (UHR) in these two groups were compared, and the best cut‐off point was determined.Results: Data related to 817 people including 96 people with metabolic syndrome and 721 people without metabolic syndrome were analysed. The mean UHR was significantly higher in patients with metabolic syndrome (14.76 ± 6.33%) compared with those without metabolic syndrome (10.0 ± 3.10%) (p < .001). People with high UHR are 2.9 times more at risk of metabolic syndrome and the best cut‐off point was 9.50% with 86% sensitivity and 55% specificity.Conclusions: According to our study, UHR is also helpful in diagnosing metabolic syndrome and can also be used to screen people at risk for metabolic syndrome.

1 October 2017
Verified
Journal Article
Closed access
MMMojgan Mohammadi
Mojgan Mohammadi
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti
MAMajid Aghadavood
Majid Aghadavood
MMMohammad Reza Mehdizadeh
Mohammad Reza Mehdizadeh
MHMohammad Mahdi Hayatbakhsh
Mohammad Mahdi Hayatbakhsh

6 January 2014 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Open access
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti
EMElham Mohammadzadeh
Elham Mohammadzadeh
KDKouros Divsalar
Kouros Divsalar
MSMostafa Shokoohi
Mostafa Shokoohi
Background: A number of abnormalities has been identified among drug addicted users especially heroin addicts. However, there are a few studies to assess the opium effects on thyroid hormones. the aim of the present study is to investigate the effect of opium on the thyroid function tests.Method: In this case–control, 50 male addicts, aged 20–50 years, with history of addiction to opium lasting more than two years, and 50 male non-addicts as control group were randomly selected. 10 cc blood sample was taken for measurements of TSH, total T4 and T3, free T4 and T3, and T3 resin uptake (T3RU) and 50 cc urine sample for opium testing.Results: The univariate analysis revealed that there was not a significant association between opium and serum levels of T4 and TSH, but compared with control group, a slight increase in total T3 and a decrease in T3RU were observed among addicts (P < 0.05). In multivariate analysis, opium was also found to exert a lowering effect on serum free T4 level after adjusting of age and cigarette smoking (P < 0.05).Conclusion: The findings of the present study demonstrated that opium can influence on thyroid function by increasing total T3 and decreasing T3RU and free T4 levels.

1 December 2018
Verified
Journal Article
Closed access
MRMaysam Rezapour
Maysam Rezapour
ASArmita Shahesmaeili
Armita Shahesmaeili
AHAli Hossinzadeh
Ali Hossinzadeh
RZRazieh Zahedi
Razieh Zahedi
HNHamid Najafipour
Hamid Najafipour
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti

27 January 2023 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
MNMohammad Javad Najafzadeh
Mohammad Javad Najafzadeh
ABAmir Baniasad
Amir Baniasad
RSReza Shahabinejad
Reza Shahabinejad
MMMahdieh Mashrooteh
Mahdieh Mashrooteh
HNHamid Najafipour
Hamid Najafipour
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti
Background: Metabolic syndrome (MetS) is a global public health concern. Chronic inflammation plays a role in MetS; haematological inflammatory parameters can be used as MetS predicting factors.Objective: Hereditary and environmental factors play an important role in the development of MetS. This study aimed to determine the relationship between haematological parameters and MetS in the adult population of southeastern Iran, Kerman.Methods: This cross‐sectional study was a sub‐analysis of 1033 subjects who participated in the second phase of the Kerman Coronary Artery Disease Risk Factor Study (KERCADRS). Metabolic syndrome was diagnosed according to Adult Treatment Panel III (ATP III) definition. Pearson correlation coefficient was used to investigate the relationship between haematological parameters with age and components of metabolic syndrome. The role of WBC, neutrophil, lymphocyte and monocyte in predicting metabolic syndrome was evaluated using the receiver operating characteristic (ROC) curve.Results: White blood cell (WBC) and its subcomponent cells count, red cell distribution width (RDW), monocyte to HDL ratio (MHR) and Neutrophil to HDL ratio (NHR) had a significant positive correlation with the severity of MetS. The cut‐off value of WBC was 6.1 (×103/μL), the sensitivity was 70%, the specificity was 52.9% for females, the cut‐off value of WBC was 6.3 (×103/μL), the sensitivity was 68.2% and the specificity was 46.7%, for males.Conclusion: WBC and its subcomponent count, RDW, MHR and NHR parameters are valuable biomarkers for further risk appraisal of MetS in adults. These markers are helpful in early diagnoses of individuals with MetS.